Welcome to our dedicated page for Integra Lifesciences Hldgs Cp news (Ticker: IART), a resource for investors and traders seeking the latest updates and insights on Integra Lifesciences Hldgs Cp stock.
Integra LifeSciences Holdings Corporation reports developments as a global medical technology company focused on neurosurgery and tissue reconstruction. News commonly covers quarterly financial results, revenue guidance, operational execution, supply reliability, quality-management work and product availability across its medical technology portfolio.
Company updates also include clinical evidence and medical-conference activity for wound reconstruction products such as PriMatrix Dermal Scaffold, Integra Dermal Matrices, Cytal Wound Matrix, MicroMatrix and AmnioExcel. Recurring corporate topics include leadership appointments, investor conference presentations, manufacturing progress and segment activity within Codman Specialty Surgical and Tissue Technologies.
Integra LifeSciences (NASDAQ: IART) will release its second quarter 2022 financial results on July 27, 2022, before the market opens. Following the release, management will hold a conference call at 8:30 a.m. ET, accessible by calling 800-289-0720 with the passcode 2688312. A webcast of the call will also be available on their website, with a replay accessible until August 7, 2022. Integra specializes in regenerative tissue technologies and offers a broad portfolio of recognized brands aimed at enhancing patient care.
On May 11, 2022, Hilco Redevelopment Partners announced that Integra LifeSciences (IART) will occupy 100,000 square feet of newly redeveloped space at 400 Wood Road in Braintree, MA. This facility will manufacture surgical reconstruction devices, contributing significantly to local job creation with at least 150 new positions. The Braintree Town Council approved a tax increment financing (TIF) agreement to support this development. Integra plans to achieve full occupancy by late 2025, aiming to positively impact the local economy.
Integra LifeSciences Holdings Corporation (IART) reported Q1 2022 revenues of $376.6 million, a 4.6% increase year-over-year. GAAP earnings per diluted share declined to $0.39 from $0.53 in Q1 2021, while adjusted EPS rose to $0.74 from $0.69. The company raised its 2022 organic growth guidance from 3.5%-5% to 3.8%-5.2% and reaffirmed total revenue growth at 2.5%-3.5%. The gross margin improved to 62.1%. Cash flow from operations was $44 million, with net debt of $1.15 billion.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) announced it will release its first quarter 2022 financial results on April 27, 2022, before the market opens. The management team will host a conference call at 8:30 a.m. ET to discuss the results. Interested parties can access the call by dialing (800)-289-0720 or via a live webcast on the company’s website. A replay will be available until May 7, 2022. Integra specializes in regenerative tissue technologies and neurosurgical solutions, offering a diverse range of high-quality brands.
Integra LifeSciences (Nasdaq: IART) has launched the NeuraGen® 3D Nerve Guide Matrix, a resorbable implant designed to repair peripheral nerve discontinuities. This innovative product combines bovine type 1 collagen with a unique inner matrix featuring porous channels, promoting Schwann cell migration and axonal growth for enhanced recovery after mid-gap nerve repairs. With approximately 50,000 nerve repair procedures performed annually, NeuraGen 3D aims to improve patient outcomes. The launch represents a significant advancement in Integra's peripheral nerve repair portfolio.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) reported its Q4 2021 and full-year results on February 23, 2022. Q4 revenues reached $405.5 million, up 4.3% year-over-year, with GAAP EPS at $0.53, down from $1.09 in Q4 2020. For the full year, revenues were $1,542.4 million, a 12.4% increase, with GAAP EPS rising to $1.98 from $1.57. The company provided 2022 guidance, projecting revenue growth of 2.5% to 3.5% and adjusted EPS between $3.27 and $3.35.
Integra LifeSciences (IART) announced preliminary revenue results for Q4 and full-year 2021, with Q4 revenue expected between $404 million and $406 million, marking a 4% increase year-over-year. Full-year revenue is projected at $1,541 million to $1,543 million, reflecting a 12% increase. The company plans a $125 million share repurchase under an existing $225 million authorization. CEO Jan De Witte expressed optimism about the company's growth strategies, including product launches and international expansion, reaffirming long-term organic growth targets of 5%-7%.
BD (Becton, Dickinson and Company) announced the formation of a nine-person board of directors for Embecta Corp., which will hold BD's Diabetes Care business after the planned spinoff. The board will be led by David F. Melcher and include notable members such as Claire Pomeroy and Christopher R. Reidy. Devdatt Kurdikar will serve as CEO of Embecta. The spinoff is expected to be completed in Q2 2022, pending regulatory approvals. The governance structure includes various committees, and directors will serve staggered terms.
Integra LifeSciences (NASDAQ: IART) reported Q3 2021 revenues of $386.9 million, up 4.5% year-over-year. GAAP diluted EPS increased to $0.51 from $0.38 in 2020, while adjusted EPS rose to $0.86 from $0.80. The company reaffirmed its 2021 revenue guidance of $1,540 million to $1,550 million and raised adjusted EPS guidance to $3.16-$3.20. Cash flow from operations hit $82.8 million, a 18.9% increase. Despite challenges, including COVID-related impacts, Integra showed strong performance in its Codman Specialty Surgical segment, buoyed by new product launches like the CereLink ICP monitor.
Integra LifeSciences Holdings Corporation has appointed Jan D. De Witte as its new President and CEO, succeeding Peter J. Arduini, who is moving to GE Healthcare. De Witte, who has over 30 years of global executive experience in healthcare and technology, previously served as CEO of Barco N.V. and held leading roles at GE. The board expressed confidence in De Witte's ability to drive innovation and stakeholder value. De Witte will officially join the company by the end of the year. This leadership transition comes as Integra aims to enhance its global impact in neurosurgery and regenerative tissue technologies.